Centro de Investigaciones Clínicas (CIC), Fundación Valle del Lili, Cra 98 No. 18-49, 760032, Cali, Colombia.
Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122-135, 760031, Cali, Colombia.
Cancer Causes Control. 2022 Mar;33(3):381-392. doi: 10.1007/s10552-021-01532-z. Epub 2022 Jan 11.
To describe our experience upon developing and implementing a hospital-based cancer registry (HBCR) in a quaternary-level of care private non-profit academic medical center in Cali, Colombia.
HBCRs capture, in a given institution, every single patient with a confirmed malignancy. In this study, all cases evaluated between 2014 and 2018 were included in the HBCR. In compliance with the International Agency for Research on Cancer recommendations, cases were classified as analytic or non-analytic. Data derived from an exhaustive selection of patients was stored in a computing platform owned by the institution, meeting the 2016 Facility Oncology Registry Data Standards recommendations. Quality control was performed by evaluating comparability, timeliness, validity, and completeness.
A total of 24,405 new cases were registered between 2014 and 2018, from which 4253 (17.4%) died. Among all cases, based on the anatomic location, most common malignancies were breast (n = 1554), thyroid (n = 1346), hematolymphoid (n = 1251), prostatic (n = 805), and colorectal (n = 624). The behavior of the new cases was consistent with an incremental trend.
Upon implementing the HBCR, major challenges were identified (i.e., a precise definition of cases, the development of processes for capturing new cases, a standardized data collection strategy, and carrying-out an appropriate patient follow-up). Based on our experience, the success of an HBCR largely relies on the interest from the institution, the engagement of stakeholders and financial support, that is, it depends on the adequate access over time to funding, technological, and staffing resources.
描述我们在哥伦比亚卡利的一家四级护理私立非营利性学术医疗中心开发和实施基于医院的癌症登记处(HBCR)的经验。
HBCR 在给定的机构中捕获每一个确诊患有恶性肿瘤的患者。在这项研究中,所有在 2014 年至 2018 年期间评估的病例都被纳入 HBCR。根据国际癌症研究机构的建议,病例被分为分析性或非分析性。从详尽选择的患者中获得的数据存储在机构拥有的计算平台中,符合 2016 年设施肿瘤学登记数据标准的建议。通过评估可比性、及时性、有效性和完整性来进行质量控制。
2014 年至 2018 年期间共登记了 24405 例新病例,其中 4253 例(17.4%)死亡。在所有病例中,根据解剖位置,最常见的恶性肿瘤是乳腺(n=1554)、甲状腺(n=1346)、血液淋巴(n=1251)、前列腺(n=805)和结直肠(n=624)。新病例的行为呈递增趋势。
在实施 HBCR 时,发现了一些主要挑战(即,病例的精确定义、捕获新病例的流程开发、标准化的数据收集策略以及进行适当的患者随访)。根据我们的经验,HBCR 的成功在很大程度上取决于机构的兴趣、利益相关者的参与和财务支持,即取决于随着时间的推移对资金、技术和人员资源的充分获取。